The concept of a “cancer stem cell system” that continues to supply cancer component cells has been proposed. It is time to apply stem cell studies, which is a field of expertise in regenerative medicine, to cancer treatment. Cancer treatments that effectively attack cancer stem cells acting as a manufacturing plant for producing differentiated cancer progenies will be designed by revealing the cancer stem cell system. Therefore, in the near future we hope that revolution will occur in cancer therapy to eradicate cancer and prevent the recurrence thereof. In this review we discuss the current situation and problems of cancer stem cell research.
Al-HajjM.; WichaM. S.; Benito-HernandezA.; MorrisonS. J.; ClarkeM. F.Prospective identification of tumorigenic breast cancer cells.Proc. Natl. Acad. Sci. USA100: 3983–3988; 2003.
2.
AyyananA.; CivenniG.; CiarloniL.; MorelC.; MuellerN.; LefortK.; MandinovaA.; RaffoulW.; FicheM.; DottoG. P.; BriskenC.Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch dependent mechanism.Proc. Natl. Acad. Sci. USA103: 3799–3804; 2006.
3.
BaoS.; WuQ.; McLendonR. E.; HaoY.; ShiQ.; HjelmelandA. B.; DewhirstM. W.; BignerD. D.; RichJ. N.Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.Nature444: 756–760; 2006.
4.
BonnetD.; DickJ. E.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.Nat. Med.3: 730–737; 1997.
5.
BruceW. R.; van der GaagH.A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo.Nature199: 79–80; 1963.
ChenL.; ShenR.; YeY.; PuX. A.; LiuX.; DuanW.; WenJ.; ZimmererJ.; WangY.; LiuY.; LaskyL. C.; HeeremaN. A.; PerrottiD.; OzatoK.; Kuramochi-MiyagawaS.; NakanoT.; YatesA. J.; CarsonW. E.III; LinH.; BarskyS. H.; GaoJ. X.Precancerous stem cells have the potential for both benign and malignant differentiation.PLoS ONE2: e293; 2007.
8.
CostelloR. T.; MalletF.; GauglerB.; SaintyD.; ArnouletC.; GastautJ. A.; OliveD.Human acute myeloid leukemia CD34+/CD38– progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities.Cancer Res.60: 4403–4411; 2000.
9.
Darash-YahanaM.; PikarskyE.; AbramovitchR.; ZeiraE.; PalB.; KarplusR.; BeiderK.; AvnielS.; KasemS.; GalunE.; PeledA.Role of high expression levels of CXCR4 in tumor growth: Vascularization, and metastasis.FASEB J.18: 1240–1242; 2004.
10.
GalliR.; BindaE.; OrfanelliU.; CipellettiB.; GrittiA.; De VitisS.; FioccoR.; ForoniC.; DimecoF.; VescoviA.Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma.Cancer Res.64: 7011–7021; 2004.
HolstC. R.; NuovoG. J.; EstellerM.; ChewK.; BaylinS. B.; HermanJ. G.; TlstyT. D.Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia.Cancer Res.63: 1596–1601; 2003.
MooreK. A.; LemischkaI. R.Stem cells and their niches.Science311: 1880–1885; 2006.
19.
NickoloffB. J.; OsborneB. A.; MieleL.Notch signaling as a therapeutic target in cancer: A new approach to the development of cell fate modifying agents.Oncogene22: 6598–6608; 2003.
20.
NishimuraE. K.; JordanS. A.; OshimaH.; YoshidaH.; OsawaM.; MoriyamaM.; JacksonI. J.; BarrandonY.; MiyachiY.; NishikawaS.Dominant role of the niche in melanocyte stem-cell fate determination.Nature416: 854–860; 2002.
21.
O'BrienC. A.; PollettA.; GallingerS.; DickJ. E.A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.Nature445: 106–110; 2007.
22.
OrimoA.; GuptaP. B.; SgroiD. C.; Arenzana-SeisdedosF.; DelaunayT.; NaeemR.; CareyV. J.; RichardsonA. L.; WeinbergR. A.Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.Cell121: 335–348; 2005.
23.
PatrawalaL.; CalhounT.; Schneider-BroussardR.; LiH.; BhatiaB.; TangS.; ReillyJ. G.; ChandraD.; ZhouJ.; ClaypoolK.; CoghlanL.; TangD. G.Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.Oncogene25: 1696–1708; 2006.
24.
PiccirilloS. G.; ReynoldsB. A.; ZanettiN.; LamorteG.; BindaE.; BroggiG.; BremH.; OliviA.; DimecoF.; VescoviA. L.Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.Nature444: 761–765; 2006.
25.
ReyaT.; MorrisonS. J.; ClarkeM. F.; WeissmanI. L.Stem cells, cancer, and cancer stem cells.Nature414: 105–111; 2001.
26.
Ricci-VitianiL.; LombardiD. G.; PilozziE.; BiffoniM.; TodaroM.; PeschleC.; De MariaR.Identification and expansion of human-colon-cancer-initiating cells.Nature445: 111–115; 2007.
27.
SinghS. K.; HawkinsC.; ClarkeI. D.; SquireJ. A.; BayaniJ.; HideT.; HenkelmanR. M.; CusimanoM. D.; DirksP. B.Identification of human brain tumour initiating cells.Nature432: 396–401; 2004.
28.
SmithM. C.; LukerK. E.; GarbowJ. R.; PriorJ. L.; JacksonE.; Piwnica-WormsD.; LukerG. D.CXCR4 regulates growth of both primary and metastatic breast cancer.Cancer Res.64: 8604–8612; 2004.
29.
SzotekP. P.; Pieretti-VanmarckeR.; MasiakosP. T.; DinulescuD. M.; ConnollyD.; FosterR.; DombkowskiD.; PrefferF.; MaclaughlinD. T.; DonahoeP. K.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness.Proc. Natl. Acad. Sci. USA103: 11154–11159; 2006.
30.
UndenA. B.; HolmbergE.; Lundh-RozellB.; Stahle-BackdahlM.; ZaphiropoulosP. G.; ToftgardR.; VorechovskyI.Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: Different in vivo mechanisms of PTCH inactivation.Cancer Res.56: 4562–4565; 1996.
31.
WeimA. L.; KimS.; WelmB. E.; BishopJ. M.MET and MYC cooperate in mammary tumorigenesis.Proc. Natl. Acad. Sci. USA102: 4324–4329; 2005.
